A Phase I Safety Study of Intramuscular CTX0E03 in Lower Limb Ischaemic Patients

This project is led by ReNeuron, a leading UK-based biotechnology business developing stem cell therapies. Critical limb ischaemia, a significant unmet medical need, is the end-stage of peripheral artery disease, resulting in poor blood flow (usually in the lower limb). The leading risk factor for this disease is Type II diabetes which has become an increasing health burden around the world.with rising rates on a global scale. Patients have limited mobility, suffer pain and have non-healing ulcers that eventually progress to gangrene leading to amputations of the limb . Stem cells offer the unique ability to change the course of the underlying disease by promoting the growth of new blood vessels in the affected limb, increasing blood flow. This project aims to take the cell therapy product, CTX-DP, currently in clinical development as a potential treatment for stroke disability, and evaluate its safety in early stage critical limb ischaemia patients in a Phase I UK clinical trial .